[
  {
    "ts": null,
    "headline": "Boston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder Case",
    "summary": "BOSTON, July 29, 2025--A Boston jury has sided with Paul and Kathryn Lovell in a lawsuit against cosmetic behemoth Johnson & Johnson (NYSE:JNJ) that asserted Mr. Lovell’s mesothelioma was directly caused by the company’s iconic, asbestos-laced baby powder. The jury awarded $42,609,300, making it what lawyers believe to be the largest mesothelioma verdict in Massachusetts history.",
    "url": "https://finnhub.io/api/news?id=44ea1bde0b751b3968b32774e43c3ac00413c6c5795a8456ae3938f44b14c471",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753830660,
      "headline": "Boston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder Case",
      "id": 136129716,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BOSTON, July 29, 2025--A Boston jury has sided with Paul and Kathryn Lovell in a lawsuit against cosmetic behemoth Johnson & Johnson (NYSE:JNJ) that asserted Mr. Lovell’s mesothelioma was directly caused by the company’s iconic, asbestos-laced baby powder. The jury awarded $42,609,300, making it what lawyers believe to be the largest mesothelioma verdict in Massachusetts history.",
      "url": "https://finnhub.io/api/news?id=44ea1bde0b751b3968b32774e43c3ac00413c6c5795a8456ae3938f44b14c471"
    }
  },
  {
    "ts": null,
    "headline": "Top Analyst Reports for Broadcom, Berkshire Hathaway & Johnson & Johnson",
    "summary": "Broadcom gains on AI chip strength and VMware synergy, while JNJ and BRK.B ride momentum despite looming headwinds.",
    "url": "https://finnhub.io/api/news?id=8cf552acecfc691796735b5c3220fbb6070187c7d2ae8f0559a99896db33ec35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753819020,
      "headline": "Top Analyst Reports for Broadcom, Berkshire Hathaway & Johnson & Johnson",
      "id": 136129560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Broadcom gains on AI chip strength and VMware synergy, while JNJ and BRK.B ride momentum despite looming headwinds.",
      "url": "https://finnhub.io/api/news?id=8cf552acecfc691796735b5c3220fbb6070187c7d2ae8f0559a99896db33ec35"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Health Care Giant J&J, Three Others In Or Near Buy Zones",
    "summary": "Dow Jones health care giant Johnson & Johnson is approaching a new buy point, while AI stocks Argan and Constellation are near buy zones.",
    "url": "https://finnhub.io/api/news?id=31c2e4a4deb70556f8f030ed9d9fb48f7e793c9995f19fa873bedfab4b38983b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753814691,
      "headline": "Dow Jones Health Care Giant J&J, Three Others In Or Near Buy Zones",
      "id": 136129718,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dow Jones health care giant Johnson & Johnson is approaching a new buy point, while AI stocks Argan and Constellation are near buy zones.",
      "url": "https://finnhub.io/api/news?id=31c2e4a4deb70556f8f030ed9d9fb48f7e793c9995f19fa873bedfab4b38983b"
    }
  },
  {
    "ts": null,
    "headline": "Analysis-The most precarious job in America's boardrooms: CEO",
    "summary": "NEW YORK (Reuters) -U.S. companies are removing their CEOs at the fastest clip in two decades, data shows, as increased scrutiny from shareholders and boards result in reduced tolerance for sub-par returns or wayward conduct.  At least 41 CEOs have exited S&P 500 companies so far this year, compared with 49 for all of 2024 – making the fastest pace on an annualized basis since 2005, according to data from nonprofit executive research group The Conference Board and data analytics company ESGAUGE.  In the latest example, consumer goods company Procter & Gamble, the maker of Tide laundry detergent and Bounty paper towels, said on Monday CEO Jon Moeller will be replaced next year by longtime executive Shailesh Jejurikar.",
    "url": "https://finnhub.io/api/news?id=9a84f2d5f9950189fadb74193139de71dbc6b60b7a37323f4c95daf5554eab03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753805438,
      "headline": "Analysis-The most precarious job in America's boardrooms: CEO",
      "id": 136119159,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW YORK (Reuters) -U.S. companies are removing their CEOs at the fastest clip in two decades, data shows, as increased scrutiny from shareholders and boards result in reduced tolerance for sub-par returns or wayward conduct.  At least 41 CEOs have exited S&P 500 companies so far this year, compared with 49 for all of 2024 – making the fastest pace on an annualized basis since 2005, according to data from nonprofit executive research group The Conference Board and data analytics company ESGAUGE.  In the latest example, consumer goods company Procter & Gamble, the maker of Tide laundry detergent and Bounty paper towels, said on Monday CEO Jon Moeller will be replaced next year by longtime executive Shailesh Jejurikar.",
      "url": "https://finnhub.io/api/news?id=9a84f2d5f9950189fadb74193139de71dbc6b60b7a37323f4c95daf5554eab03"
    }
  },
  {
    "ts": null,
    "headline": "Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch",
    "summary": "MONTPELLIER, France, July 29, 2025--Regulatory News: Medincell (Paris:MEDCL):",
    "url": "https://finnhub.io/api/news?id=c4f0d681e72ec56047499f3ee0604ec5bcaa290900c8dcd598e3ea328dc0dd03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753803900,
      "headline": "Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch",
      "id": 136119160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MONTPELLIER, France, July 29, 2025--Regulatory News: Medincell (Paris:MEDCL):",
      "url": "https://finnhub.io/api/news?id=c4f0d681e72ec56047499f3ee0604ec5bcaa290900c8dcd598e3ea328dc0dd03"
    }
  },
  {
    "ts": null,
    "headline": "Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.",
    "summary": "There is a growing list of challenges to drugs and programs Merck hopes will take up the slack from Keytruda.",
    "url": "https://finnhub.io/api/news?id=2882e025de234379523055e798c0734413f211014488659f7fbc8603b3ac1eda",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753802160,
      "headline": "Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.",
      "id": 136119118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "There is a growing list of challenges to drugs and programs Merck hopes will take up the slack from Keytruda.",
      "url": "https://finnhub.io/api/news?id=2882e025de234379523055e798c0734413f211014488659f7fbc8603b3ac1eda"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions",
    "summary": "Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the VIRTUGUIDE™ System. This AI-powered, patient-matched solution is designed to support Lapidus procedures2, a type of bunion surgery that helps realign the foot by joining two bones near the arch (the first metatarsal bone and the medial cuneiform).3 The system uses pre-operative planning software, developed in collaboration with PeekMed®, to asses",
    "url": "https://finnhub.io/api/news?id=e0f080b39dcfd78d988acec883d12178353797aa439fd5e0f3d6876dc44bad99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753790580,
      "headline": "Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions",
      "id": 136116970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the VIRTUGUIDE™ System. This AI-powered, patient-matched solution is designed to support Lapidus procedures2, a type of bunion surgery that helps realign the foot by joining two bones near the arch (the first metatarsal bone and the medial cuneiform).3 The system uses pre-operative planning software, developed in collaboration with PeekMed®, to asses",
      "url": "https://finnhub.io/api/news?id=e0f080b39dcfd78d988acec883d12178353797aa439fd5e0f3d6876dc44bad99"
    }
  },
  {
    "ts": null,
    "headline": "Cybersecurity Trailblazer Marene Allison Joins Sicura as Strategic Advisor to Advance Security Control Management",
    "summary": "Sicura, defining the future of Security Control Management, today announced that Marene Allison, former chief information security officer (CISO) at Johnson & Johnson, has joined the company as a strategic advisor. With four decades of experience protecting some of the world's most sensitive environments, Allison will offer Sicura critical strategic support for product, go-to-market and industry engagement.",
    "url": "https://finnhub.io/api/news?id=a643a9f4cc08e1d3d7e3d8f34510a3210d50e558ed27479a0b67f219690cedbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753790520,
      "headline": "Cybersecurity Trailblazer Marene Allison Joins Sicura as Strategic Advisor to Advance Security Control Management",
      "id": 136116971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Sicura, defining the future of Security Control Management, today announced that Marene Allison, former chief information security officer (CISO) at Johnson & Johnson, has joined the company as a strategic advisor. With four decades of experience protecting some of the world's most sensitive environments, Allison will offer Sicura critical strategic support for product, go-to-market and industry engagement.",
      "url": "https://finnhub.io/api/news?id=a643a9f4cc08e1d3d7e3d8f34510a3210d50e558ed27479a0b67f219690cedbf"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval to include new evidence in the TREMFYA® (guselkumab) label for the inhibition of progression of structural damage in adults with active psoriatic arthritis (PsA).",
    "url": "https://finnhub.io/api/news?id=a19561c23989b5614f35337e43fb50edb3212d92bacac92efe746b3874ad3e48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753790400,
      "headline": "Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis",
      "id": 136116972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval to include new evidence in the TREMFYA® (guselkumab) label for the inhibition of progression of structural damage in adults with active psoriatic arthritis (PsA).",
      "url": "https://finnhub.io/api/news?id=a19561c23989b5614f35337e43fb50edb3212d92bacac92efe746b3874ad3e48"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results",
    "summary": "RAHWAY, N.J., July 29, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results",
    "url": "https://finnhub.io/api/news?id=7904268f83595b9602a8ec95df43013a63d0afb69de78f4bb3ffa2a777322a75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753785000,
      "headline": "Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results",
      "id": 136116973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., July 29, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results",
      "url": "https://finnhub.io/api/news?id=7904268f83595b9602a8ec95df43013a63d0afb69de78f4bb3ffa2a777322a75"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Income Fund Q2 2025 Commentary",
    "summary": "US stocks advanced during the second quarter of 2025 as equity markets rebounded from Aprilâs lows and continued to rally through June, despite bouts of volatility.",
    "url": "https://finnhub.io/api/news?id=da0dbacd777c2f6ccb23261d15768f51b81587626d916c67f2edf73873cfdaa1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753777200,
      "headline": "Franklin Income Fund Q2 2025 Commentary",
      "id": 136116824,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359134494/image_1359134494.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "US stocks advanced during the second quarter of 2025 as equity markets rebounded from Aprilâs lows and continued to rally through June, despite bouts of volatility.",
      "url": "https://finnhub.io/api/news?id=da0dbacd777c2f6ccb23261d15768f51b81587626d916c67f2edf73873cfdaa1"
    }
  },
  {
    "ts": null,
    "headline": "New Drug, New Direction: J&J Moves Deeper Into Late-Stage Therapeutics",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best trade‑war resistant stocks to buy now. On July 21, 2025, J&J submitted a New Drug Application to the U.S. FDA for icotrokinra, an oral peptide therapy targeting moderate to severe plaque psoriasis in patients aged 12 and older—signaling a strong late‑stage R&D pipeline with growth potential beyond consumer […]",
    "url": "https://finnhub.io/api/news?id=b0d743b6a7d6c3f6d390250c887baa2d1e2c37d6b8983cb6923dda961336c4e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753769199,
      "headline": "New Drug, New Direction: J&J Moves Deeper Into Late-Stage Therapeutics",
      "id": 136116974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best trade‑war resistant stocks to buy now. On July 21, 2025, J&J submitted a New Drug Application to the U.S. FDA for icotrokinra, an oral peptide therapy targeting moderate to severe plaque psoriasis in patients aged 12 and older—signaling a strong late‑stage R&D pipeline with growth potential beyond consumer […]",
      "url": "https://finnhub.io/api/news?id=b0d743b6a7d6c3f6d390250c887baa2d1e2c37d6b8983cb6923dda961336c4e6"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Upgraded to Buy as Growth and Margins Impress Analysts",
    "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the stocks to benefit from an onshoring boom. On July 23, Erste Group raised the stock rating of Johnson & Johnson (NYSE:JNJ) from Hold to Buy. The firm attributed the upgrade decision in large part to Johnson & Johnson’s superior operating margin and return on equity when compared to […]",
    "url": "https://finnhub.io/api/news?id=9e848b93097aa579b73b6879041d5ac2f29a4ae917dbf3b11ec75bb8f5acf440",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753767440,
      "headline": "Johnson & Johnson (JNJ) Upgraded to Buy as Growth and Margins Impress Analysts",
      "id": 136113401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the stocks to benefit from an onshoring boom. On July 23, Erste Group raised the stock rating of Johnson & Johnson (NYSE:JNJ) from Hold to Buy. The firm attributed the upgrade decision in large part to Johnson & Johnson’s superior operating margin and return on equity when compared to […]",
      "url": "https://finnhub.io/api/news?id=9e848b93097aa579b73b6879041d5ac2f29a4ae917dbf3b11ec75bb8f5acf440"
    }
  },
  {
    "ts": null,
    "headline": "2 Unstoppable Dow Dividend Stocks to Buy and Hold Forever",
    "summary": "These top Dow dividend stocks have long dividend growth streaks.",
    "url": "https://finnhub.io/api/news?id=5cad6e396fb63e069f9bd7737a42b8251cc427e982bbb0687b6bd9b5f17ace87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753748940,
      "headline": "2 Unstoppable Dow Dividend Stocks to Buy and Hold Forever",
      "id": 136113402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "These top Dow dividend stocks have long dividend growth streaks.",
      "url": "https://finnhub.io/api/news?id=5cad6e396fb63e069f9bd7737a42b8251cc427e982bbb0687b6bd9b5f17ace87"
    }
  },
  {
    "ts": null,
    "headline": "Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever",
    "summary": "If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.",
    "url": "https://finnhub.io/api/news?id=804e7c1014333557f0f08020643bf2a5c45ab61dbdd25651723cd5752e44fd7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753747500,
      "headline": "Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever",
      "id": 136113403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.",
      "url": "https://finnhub.io/api/news?id=804e7c1014333557f0f08020643bf2a5c45ab61dbdd25651723cd5752e44fd7b"
    }
  },
  {
    "ts": null,
    "headline": "BME: The Resilient Income Investment Of The Healthcare Industry",
    "summary": "BlackRock Health Sciences Trust offers a resilient 8.63% dividend yield, low expense ratio, and conservative, low-risk positioning. See more on BME ETF here.",
    "url": "https://finnhub.io/api/news?id=78240d01203e7108640de3e61a12e015ad3c84d30c01e10965bf01bcf0b6bbe0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753747321,
      "headline": "BME: The Resilient Income Investment Of The Healthcare Industry",
      "id": 136112843,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Trust offers a resilient 8.63% dividend yield, low expense ratio, and conservative, low-risk positioning. See more on BME ETF here.",
      "url": "https://finnhub.io/api/news?id=78240d01203e7108640de3e61a12e015ad3c84d30c01e10965bf01bcf0b6bbe0"
    }
  }
]